|
|
|
|
|
|
Sponsored by: |
Merck |
Information provided by: | Merck |
ClinicalTrials.gov Identifier: | NCT00396175 |
A clinical study to collect additional data in order to characterize the reduction in PSA with finasteride 1 mg, and its reversibility in men with androgenetic alopecia between the ages of 40 to 60 years.
Condition | Intervention | Phase |
Androgenetic Alopecia |
Drug: MK0906, finasteride / Duration of Treatment : 48 Weeks Drug: Comparator : placebo (unspecified) / Duration of Treatment : 48 Weeks |
Phase III |
Genetics Home Reference related topics: | androgenetic alopecia |
MedlinePlus related topics: | Hair Diseases and Hair Loss |
Drug Information available for: | Finasteride |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety Study |
Official Title: | A Double-Blind, Placebo-Controlled, Multicenter Study To Examine the Effects of Finasteride 1 MG on Serum Prostate-Specific Antigen in Men With Androgenetic Alopecia |
Ages Eligible for Study: | 40 Years to 60 Years |
Genders Eligible for Study: | Male |
Accepts Healthy Volunteers: | No |
Inclusion Criteria :
Exclusion Criteria :
Study ID Numbers: | 2006_556 |
First Received: | November 2, 2006 |
Last Updated: | November 2, 2006 |
ClinicalTrials.gov Identifier: | NCT00396175 |
Health Authority: | United States: Food and Drug Administration |
|
|